Program Description
In 2025, several new medications were approved by the Food and Drug Administration (FDA) with oncology indications. Pharmacists, as integral members of the health care team, must stay informed about these new approvals to provide optimal patient care. This activity will focus on the identification and review of selected new medications for cancers approved by the FDA in 2025. Understanding the indications along with a review of key characteristics of these medications, including their dosing regimens, administration methods, and safety profiles, is crucial for oncology pharmacists to recommend appropriate therapies and ensure patients receive the most effective treatments. This activity will equip pharmacists and pharmacy technicians with valuable insights into the latest approved oncology medications, so they may appropriately implement them into patient care to improve health outcomes. Staying current with these innovations is vital for oncology pharmacists to maintain their role as knowledgeable and trusted health care providers.
Target Audience: Ambulatory care, community, health-system, and specialty pharmacists, and pharmacy technicians
Type of Activity: Knowledge
Release date: February 1, 2026
Expiration date: February 1, 2027
Learner level: Foundational
Time to complete activity: 2.0 hours
Fee: Free
Educational Objectives
At the completion of this activity, participants will be able to:
- Discuss the clinical indications and common adverse effects of new drugs approved for oncology indications by the FDA in 2025
- Point out important aspects of newly approved drugs, including dosing, administration, and safety profiles, to properly assess, counsel, and monitor patients on therapy
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here